Syros Pharmaceuticals Inc (SYRS) Return on Investment ROI from the third quarter of 2024 to third quarter of 2023 and for the year 2024, average high and low, overall ranking from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Syros Pharmaceuticals Inc   (NASDAQ: SYRS)


Syros Pharmaceuticals Inc's ROI from its third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Syros Pharmaceuticals Inc's ROI in the third quarter of 2024?
Syros Pharmaceuticals Inc recorded a cumulative net loss of $-98 million during 12 months ending in the third quarter of 2024, resulting in a negative return on investment (ROI) of -243.74%.

Within the Healthcare sector 865 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2024 from 4124 to 4596.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter
Y / Y Investment Change TTM -68.16 % -65.51 % -49.96 % -29.63 % -5.4 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 30 35 45 51 76
Return On Investment (TTM) -243.74 % -255.12 % -202.19 % -170.12 % -83.28 %
SYRS's Overall Ranking # 4596 # 4124 # 0 # 0 # 4206
Seq. Investment Change TTM -22.18 % -27.84 % -26.13 % -23.24 % -15.71 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -98 -132 -144 -165 -105

SYRS Company Profile >> Back to SYRS Roi Comparisons >> See Annual SYRS Return On Investment



Return On Investment SYRS's Ranking
Within: No.
Industry # 423
Sector # 866
Overall # 4596

Return On Investment Statistics
High Average Low
-44.16 %
-91.11 %
-315.05 %
(Dec 31 2021)   (Dec 31 2016)



  News about Syros Pharmaceuticals Inc Return on Investment ROI

Syros Pharmaceuticals Faces Challenge with SELECT-MDS-1 Phase 3 Trial Results, Yet Remains Focused on Future Growth

November 13, 2024

Syros Pharmaceuticals, a biopharmaceutical company specializing in the development of treatments for hematologic malignancies, recently announced topline data from their SELECT-MDS-1 Phase 3 trial. The trial investigated tamibarotene, combined with azacitidine, in treating newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. Unfortunately, the trial did not meet its primary endpoint of achieving a significant complete response (CR) rate, presenting a challenge for the company s therapeutic portfolio. Phase 3 Trial Results: The SELECT-MDS-1 Phase 3 trial aimed to establish tamibarotene s efficacy in combination with azacitidine over existing treatments for HR-MDS patients with RARA gene overexpression. Despite the promising preclinical and earlier phase results, this trial did not achieve the expected CR rate, a primary endpoint indicating the percentage of patients who achieve complete remission from the disease.





Financial Statements
Syros Pharmaceuticals Inc's III. Quarter Investments $ 30 Millions SYRS's Balance sheet
Syros Pharmaceuticals Inc's III. Quarter Income $ -6 Millions Quarterly SYRS's Income Statement
SYRS's Income by Division See SYRS's Income by Division


SYRS Annual Return On Investment (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Investments in Millions 51 168 151 185 126
Y / Y Investment Growth -69.58 % 11.2 % -17.98 % 45.99 % 60.16 %
Net Income in Millions -165 -95 -87 -84 -75
Y / Y Net Income Growth - - - - -
Annual Return On Investment -321.32 % -56.21 % -57.16 % -45.52 % -59.65 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SYRS's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SYRS's Competitors
Subscribers only: Roi for Syros Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for SYRS's Customers

Other Ratios
SYRS's Roa SYRS's Inventory Turnover Ratio SYRS's Growth Rates SYRS's Dividend Statistics
SYRS's Profitability Ratios SYRS's Asset Turnover Ratio SYRS's Dividend Growth
SYRS's Roe SYRS's Valuation Ratios SYRS's Financial Strength Ratios SYRS's Dividend Payout Ratio



Companies with similar Return On Investment at Sep 30 2024, within Healthcare Sector ROI

Date modified: 2026-09-26T07:31:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.